CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CRISPR Therapeutics AG
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$50.04+0.79 (+1.60%)
Close on Oct 19, 2026
- Market cap
- $4.83B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns CRISPR Therapeutics's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 25 sales
Net sold $14.46M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 7,987,262 | 8.30% | 13G (passive) amendment | Jun 30, 2026 |
| Orbis Investment Management Ltd | 5,433,344 | 5.60% | 13G (passive) amendment | Jun 30, 2026 |
| Capital World Investors | 4,929,428 | 5.10% | 13G (passive) | Mar 31, 2026 |
| ARK Investment Management LLC | 11,313,623 | 11.79% | 13G (passive) amendment | Mar 31, 2026 |
| Catherine D. Wood | 10,165,400 | 11.85% | 13G (passive) amendment | Mar 31, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Samarth Kulkarni | Chief Executive Officer, Director | 341,123 | 0.35% | Mar 24, 2026 |
| James R. Kasinger | General Counsel and Secretary | 105,184 | 0.11% | Sep 24, 2026 |
| Raju Prasad | Chief Financial Officer | 14,815 | 0.02% | Aug 11, 2026 |
| Naimish Patel | Chief Medical Officer | 19,357 | 0.02% | Jun 2, 2026 |
| Julianne Bruno | Chief Operating Officer | 17,632 | 0.02% | Mar 24, 2025 |
| Ali Behbahani | Director | 345 | 0.00% | Sep 21, 2026 |
| Douglas A. Treco | Director | 22,000 | 0.02% | Jun 9, 2026 |
| Harold Edward Fleming | Director | – | – | Jun 9, 2026 |
| Christian Rommel | Director | – | – | Jun 9, 2026 |
| John Greene | Director | 7,000 | 0.01% | Jun 9, 2026 |
| Maria Fardis | Director | – | – | Jun 9, 2026 |
| Sandesh Mahatme | Director | – | – | Jun 9, 2026 |
| Simeon George | Director | 2,038,763 | 2.11% | Jun 9, 2026 |
| Briggs Morrison | Director | 5,209 | 0.01% | Jun 9, 2026 |
| Katherine A. High | Director | – | – | Jun 9, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| James R. Kasinger General Counsel and Secretary | Sep 22, 2026 | Option exercise | +10,400 | $13.62 | $141.65K | 105,184 |
| James R. Kasinger General Counsel and Secretary | Sep 22, 2026 | Sale(10b5-1 plan) | −10,400 | $60.24 | $626.50K | 94,784 |
| Ali Behbahani Director | Sep 17, 2026 | Option exercise | +30,000 | $14.00 | $420.00K | 30,316 |
| Ali Behbahani Director | Sep 17, 2026 | Sale | −13,679 | $57.09 | $780.93K | 16,637 |
| Raju Prasad Chief Financial Officer | Aug 7, 2026 | Gift | −750 | – | – | 14,815 |
| Naimish Patel Chief Medical Officer | May 29, 2026 | Sale | −3,786 | $55.62 | $210.58K | 19,357 |
| Naimish Patel Chief Medical Officer | May 28, 2026 | Option exercise | +10,000 | – | – | 23,143 |
| Raju Prasad Chief Financial Officer | Mar 23, 2026 | Sale | −3,708 | $46.78 | $173.46K | 15,565 |
| James R. Kasinger General Counsel and Secretary | Mar 23, 2026 | Sale | −3,182 | $46.78 | $148.85K | 94,308 |
| Samarth Kulkarni Chief Executive Officer, Director | Mar 23, 2026 | Sale | −10,020 | $46.78 | $468.74K | 255,501 |
| Raju Prasad Chief Financial Officer | Mar 20, 2026 | Option exercise | +6,250 | – | – | 19,273 |
| James R. Kasinger General Counsel and Secretary | Mar 20, 2026 | Option exercise | +6,250 | – | – | 97,490 |
| Samarth Kulkarni Chief Executive Officer, Director | Mar 20, 2026 | Option exercise | +19,687 | – | – | 265,521 |
| Raju Prasad Chief Financial Officer | Mar 16, 2026 | Sale | −4,021 | $48.26 | $194.05K | 13,773 |
| Raju Prasad Chief Financial Officer | Mar 16, 2026 | Gift | −750 | – | – | 13,023 |
| Raju Prasad Chief Financial Officer | Mar 16, 2026 | Sale | −5,848 | $48.26 | $282.22K | 17,794 |
| Naimish Patel Chief Medical Officer | Mar 16, 2026 | Sale | −3,150 | $48.26 | $152.02K | 13,143 |
| Samarth Kulkarni Chief Executive Officer, Director | Mar 16, 2026 | Sale | −10,349 | $48.26 | $499.44K | 245,834 |
| James R. Kasinger General Counsel and Secretary | Mar 16, 2026 | Sale | −3,450 | $48.26 | $166.50K | 91,240 |
| Raju Prasad Chief Financial Officer | Mar 14, 2026 | Option exercise | +10,000 | – | – | 16,767 |
| Raju Prasad Chief Financial Officer | Mar 14, 2026 | Option exercise | +6,875 | – | – | 23,642 |
| Naimish Patel Chief Medical Officer | Mar 14, 2026 | Option exercise | +8,125 | – | – | 16,293 |
| Samarth Kulkarni Chief Executive Officer, Director | Mar 14, 2026 | Option exercise | +20,625 | – | – | 256,183 |
| James R. Kasinger General Counsel and Secretary | Mar 14, 2026 | Option exercise | +6,875 | – | – | 94,690 |
| Samarth Kulkarni Chief Executive Officer, Director | Mar 11, 2026 | Sale | −9,798 | $52.80 | $517.33K | 235,558 |
| James R. Kasinger General Counsel and Secretary | Mar 11, 2026 | Sale | −2,800 | $52.80 | $147.84K | 87,815 |
| Samarth Kulkarni Chief Executive Officer, Director | Mar 10, 2026 | Option exercise | +19,250 | – | – | 245,356 |
| James R. Kasinger General Counsel and Secretary | Mar 10, 2026 | Option exercise | +5,500 | – | – | 90,615 |
| James R. Kasinger General Counsel and Secretary | Feb 19, 2026 | Sale | −2,112 | $52.58 | $111.05K | 85,115 |
| Samarth Kulkarni Chief Executive Officer, Director | Feb 19, 2026 | Sale | −6,967 | $52.58 | $366.32K | 226,106 |
| James R. Kasinger General Counsel and Secretary | Feb 18, 2026 | Option exercise | +3,825 | – | – | 87,227 |
| Samarth Kulkarni Chief Executive Officer, Director | Feb 18, 2026 | Option exercise | +13,250 | – | – | 233,073 |
| Raju Prasad Chief Financial Officer | Jan 22, 2026 | Sale(10b5-1 plan) | −34,972 | $60.19 | $2.10M | 6,767 |
| Raju Prasad Chief Financial Officer | Jan 22, 2026 | Option exercise | +34,972 | $45.15 | $1.58M | 41,739 |
| Samarth Kulkarni Chief Executive Officer, Director | Jan 22, 2026 | Sale(10b5-1 plan) | −60,000 | $60.23 | $3.61M | 134,201 |
| Samarth Kulkarni Chief Executive Officer, Director | Jan 20, 2026 | Sale(10b5-1 plan) | −8,567 | $52.10 | $446.34K | 194,201 |
| Samarth Kulkarni Chief Executive Officer, Director | Jan 20, 2026 | Sale(10b5-1 plan) | −21,433 | $51.61 | $1.11M | 202,768 |
| Raju Prasad Chief Financial Officer | Jan 6, 2026 | Sale(10b5-1 plan) | −18,933 | $60.18 | $1.14M | 17,534 |
| Raju Prasad Chief Financial Officer | Jan 6, 2026 | Sale(10b5-1 plan) | −5,004 | $60.00 | $300.24K | 12,530 |
| Raju Prasad Chief Financial Officer | Jan 6, 2026 | Sale(10b5-1 plan) | −5,763 | $60.21 | $346.99K | 6,767 |
| Raju Prasad Chief Financial Officer | Jan 6, 2026 | Option exercise | +6,339 | $44.31 | $280.88K | 36,467 |
| Raju Prasad Chief Financial Officer | Jan 6, 2026 | Option exercise | +23,361 | $45.15 | $1.05M | 30,128 |
| Raju Prasad Chief Financial Officer | Dec 22, 2025 | Sale(10b5-1 plan) | −5,472 | $56.33 | $308.24K | 7,767 |
| Raju Prasad Chief Financial Officer | Dec 22, 2025 | Sale(10b5-1 plan) | −1,000 | $56.89 | $56.89K | 6,767 |
| Raju Prasad Chief Financial Officer | Dec 22, 2025 | Sale(10b5-1 plan) | −3,528 | $55.10 | $194.39K | 13,239 |
| Samarth Kulkarni Chief Executive Officer, Director | Dec 18, 2025 | Gift | −30,000 | – | – | 224,201 |
| Samarth Kulkarni Chief Executive Officer, Director | Oct 17, 2025 | Sale | −50,895 | $67.91 | $3.46M | 254,201 |
| Samarth Kulkarni Chief Executive Officer, Director | Oct 16, 2025 | Option exercise | +100,000 | – | – | 305,096 |
| James R. Kasinger General Counsel and Secretary | Oct 14, 2025 | Sale | −1,076 | $66.60 | $71.66K | 83,402 |
| Samarth Kulkarni Chief Executive Officer, Director | Oct 14, 2025 | Sale | −4,242 | $66.60 | $282.52K | 205,096 |
| James R. Kasinger General Counsel and Secretary | Oct 13, 2025 | Option exercise | +2,114 | – | – | 84,478 |
| Samarth Kulkarni Chief Executive Officer, Director | Oct 13, 2025 | Option exercise | +8,334 | – | – | 209,338 |
| Samarth Kulkarni Chief Executive Officer, Director | Sep 17, 2025 | Gift | −6,000 | – | – | 201,004 |
| Samarth Kulkarni Chief Executive Officer, Director | Aug 18, 2025 | Sale | −13,081 | $58.15 | $760.66K | 207,004 |
| Samarth Kulkarni Chief Executive Officer, Director | Aug 16, 2025 | Option exercise | +25,000 | – | – | 220,085 |
| Ali Behbahani Director | Aug 6, 2025 | Other | +15 | – | – | 29 |
| Ali Behbahani Director | Aug 6, 2025 | Other | +60 | – | – | 316 |
| Douglas A. Treco Director | Aug 6, 2025 | Buy | +20,000 | $57.03 | $1.14M | 22,000 |
| Simeon George Director | Jul 16, 2025 | Buy | +6,510 | $52.03 | $338.72K | 69,687 |
| Simeon George Director | Jul 16, 2025 | Buy | +960,983 | $52.03 | $50.00M | 1,730,179 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| George Simeon Director | Oct 14, 2026 | 14,514 | $720.37K | Oct 14, 2026 | Stock Option Exercise |
| Kasinger James Officer | Oct 6, 2026 | 1,990 | $119.48K | Oct 6, 2026 | Stock Option Exercise |
| Kasinger James Officer | Sep 22, 2026 | 10,400 | $626.46K | Sep 22, 2026 | Stock Option Exercise |
| Behbahani Ali Director | Sep 17, 2026 | 13,679 | $780.94K | Sep 17, 2026 | Stock Option Exercise |
| Prasad Raju Officer | Jan 22, 2026 | 34,972 | $2.11M | Jan 22, 2026 | Stock Option Exercise |
| Kulkarni Samarth Officer | Jan 22, 2026 | 60,000 | $3.65M | Jan 22, 2026 | Acquired as compensation -- Restricted Stock Awards |
| Kulkarni Samarth Officer | Jan 20, 2026 | 30,000 | $1.58M | Jan 20, 2026 | Acquired as compensation -- Restricted Stock Awards |
| Prasad Raju Officer | Jan 6, 2026 | 29,700 | $1.79M | Jan 6, 2026 | Stock Option Exercise |
| Prasad Raju Officer | Dec 22, 2025 | 10,000 | $559.55K | Dec 22, 2025 | Restricted Stock |
| Kulkarni Samarth Officer | Feb 18, 2025 | 45,000 | $2.35M | Feb 18, 2025 | Acquired as compensation -- Restricted Stock Awards |
| Samarth Kulkarni Dr. Officer | Nov 12, 2024 | 75,000 | $4.11M | Nov 11, 2024 | Acquired as compensation -- Restricted Stock Awards |
| Kulkarni Samarth Officer, Director | Apr 15, 2024 | 19,582 | $1.17M | Apr 15, 2024 | Stock Option Exercise |
| Khanh Morrow Phuong Officer | Mar 22, 2024 | 50,767 | $3.70M | Mar 22, 2024 | Stock Option Exercise |
| Kulkarni Samarth Officer, Director | Mar 15, 2024 | 20,000 | $1.45M | Mar 15, 2024 | Stock Option Exercise |
| Kulkarni Samarth Officer, Director | Feb 15, 2024 | 20,000 | $1.61M | Feb 15, 2024 | Stock Option Exercise |